Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
NCT03222674
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL:
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Sponsor
Shenzhen Geno-Immune Medical Institute
Collaborators
[object Object]
[object Object]